- In late March 2026, Oklo Inc. and Sweden’s Blykalla AB expanded their transatlantic partnership to collaborate on fast reactor commercialization, with Blykalla planning US$100–200 million of potential U.S. investments and committing 30–40 engineers to support Oklo’s DOE‑authorized reactor pilot and related technical workstreams.
- This deeper collaboration not only aims to speed Oklo’s technology development and enable fast‑neutron irradiation testing, but also highlights how external capital and engineering resources could bolster the company’s U.S. deployment ambitions while it remains pre‑commercial and heavily scrutinized by analysts and media commentators.
- We’ll now examine how this expanded Blykalla collaboration, against ongoing concerns about Oklo’s commercialization timeline, could influence its investment narrative.
This technology could replace computers: discover 23 stocks that are working to make quantum computing a reality.
Oklo Investment Narrative Recap
To own Oklo, you have to believe that advanced microreactors can move from “science project” to operating assets, supported by federal programs and long term power contracts, before funding needs or regulatory friction bite too hard. The expanded Blykalla partnership adds engineering depth and potential US$100–200 million of outside capital, but it does not alter the fact that Oklo’s most important near term catalyst remains securing commercial NRC approvals, while execution delays across multiple projects are still the defining risk.
The recent DOE approvals for the Aurora Powerhouse design and Atomic Alchemy’s Groves Isotopes Test Reactor look particularly relevant alongside the Blykalla news. Together, they frame a picture of incremental technical and regulatory progress around Oklo’s core power and isotope platforms, which feeds directly into the key catalysts investors are watching: moving Aurora INL toward operation, proving fuel and irradiation capabilities, and ultimately converting parts of the 14 gigawatt pipeline into firm, long duration contracts.
Yet beneath the promise of new partners and federal support, investors should also be aware of the risk that...
Read the full narrative on Oklo (it's free!)
Oklo's narrative projects $51.8 million in revenue and $7.5 million in earnings by 2029. This implies an increase in earnings of about $84.1 million from -$76.6 million today.
Uncover how Oklo's forecasts yield a $112.13 fair value, a 123% upside to its current price.
Exploring Other Perspectives
Some of the most optimistic analysts were assuming Oklo could reach about US$115.7 million in revenue and US$16.8 million in earnings by 2029, which is far more upbeat than the baseline narrative and heavily tied to policy acceleration and integrated fuel capabilities. The expanded Blykalla collaboration could reinforce that view or expose how dependent it is on smooth fuel cycle progress, reminding you that reasonable people can look at the same stock and reach very different conclusions.
Explore 55 other fair value estimates on Oklo - why the stock might be worth less than half the current price!
Form Your Own Verdict
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Oklo research is our analysis highlighting 1 key reward and 5 important warning signs that could impact your investment decision.
- Our free Oklo research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Oklo's overall financial health at a glance.
No Opportunity In Oklo?
Our top stock finds are flying under the radar-for now. Get in early:
- Find 64 companies with promising cash flow potential yet trading below their fair value.
- Outshine the giants: these 19 early-stage AI stocks could fund your retirement.
- AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com